Multiple sclerosis therapy Early use of highly effective therapies Neurology Partner Content RX View Post
View Post This content is machine translated The ASCLEPIOS studies Ofatumumab has the potential to be a game changer Prof. Ludwig Kappos, M.D., Basel, Switzerland, together with Prof. Stephen L. Hauser, M.D., Director of the UCSF Weill Institute for Neurosciences, San Francisco, USA, chaired the Steering Committee of the two studies ASCLEPIOS I and II. These studies evaluated ofatumumab compared with teriflunomide in patients with relapsing-remitting multiple sclerosis (RMS) [1]. In the following interview, he describes the specific properties of this anti-CD20 antibody, explains the most important study results and describes his personal experience with ofatumumab. View Post
View Post This content is machine translated KESIMPTA® (ofatumumab) for the treatment of relapsing-remitting multiple sclerosis KESIMPTA® (ofatumumab) shows superior efficacy to teriflunomide even in therapy-naïve patients What benefits can patients with relapsing-remitting multiple sclerosis (RMS) expect from first-line treatment with ofatumumab (KESIMPTA®)? The answer to this question was provided by a subgroup analysis of data from treatment-naive patients in the two ASCLEPIOS trials. Here, patients on ofatumumab were shown to have lower disease activity and slower progression compared with teriflunomide. Tolerability was comparable to the overall study population and adherence was correspondingly high. View Post
View Post This content is machine translated KESIMPTA® (ofatumumab) for the treatment of relapsing-remitting multiple sclerosis High efficacy with good tolerability For patients with relapsing-remitting multiple sclerosis (RMS), KESIMPTA® (ofatumumab) has recently become the first subcutaneous antibody-based therapy option available. In the ASCLEPIOS I and II trials, ofatumumab was shown to have superior efficacy compared with teriflunomide. The good effect was not at the expense of tolerability. View Post